Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms

NCT07079215 · tracked via the Priya Life Science South Korea tracker
Sponsor
Nu Eyne Co., Ltd
Phase
Not applicable
Started
2025-05-30
Last updated
2025-07-22

Condition(s) studied

Opioid Withdrawal (Disorder)Opioid Use Disorder

Investigational drug(s) / intervention(s)

NeurostimulationSham stimulation

Neurostimulation: Participants in this group will use the physical device for medical use (ADTPM 1) applied to the auricular region (ear and surrounding area) for 60 minutes (±10 minutes) per session, at least once daily and a minimum of 7 times per week, over a 4-week treatment period. Additional sessions may be conducted if participants require further relief of withdrawal symptoms. All assessments and permitted concomitant treatments will be administered in accordance with the study protocol.

Sham stimulation: Control Group (Sham Stimulation, n=12): Participants in this group will use a sham stimulation device that does not deliver active stimulation. The sham device will be applied under the same schedule and conditions-60 minutes (±10 minutes) per session, at least once daily and 7 times per week for 4 weeks. All assessments and permitted concomitant treatments will be identical to those in the active stimulation group.

Study summary

This study aims to evaluate the safety and efficacy of a physical device for medical use (ADTPM 1) applied to opioid withdrawal symptoms.

Eligibility

Sex
ALL
Min age
19 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Participants aged 19 to 80 years 2. Participants currently dependent on opioids, whether prescribed or non-prescribed 3. Participants who meet the criteria for opioid use disorder (OUD) according to DSM-5 4. Participants with a Clinical Opiate Withdrawal Scale (COWS) score of 5 or higher 5. Participants with a Numeric Rating Scale (NRS) pain score of less than 6 6. Participants who have voluntarily decided to participate in the study and have provided written informed consent 7. Participants who are willing to comply with the study protocol Exclusion Criteria: 1. Participants with any current uncontrolled or clinically significant medical condition 2. Participants with a history of seizures or epilepsy 3. Participants with a history of neurological disorders or traumatic brain injury 4. Participants who have used long-acting opioids, such as methadone or buprenorphine, continuously for more than 5 days prior to screening 5. Participants who have used methadone within 30 days prior to screening 6. Participants who have used buprenorphine within 7 days prior to screening 7. Participants with physiological dependence on alcohol or drugs other than opioids, tobacco, or marijuana 8. Participants diagnosed with a major psychiatric disorder (psychosis, schizophrenia, or bipolar disorder) 9. Participants who are currently hospitalized due to a recent suicide attempt or who are persistently expressing suicidal intent 10. Participants with implanted devices such as a pacemaker, cochlear implant, or neurostimulator. 11. Participants with abnormal ear anatomy or ear infections 12. Participants diagnosed with renal or hepatic failure 13. Participants who are currently undergoing chemotherapy (Exception: Participation may be allowed if the investigator determines that participation poses no medical safety concerns for the participant) 14. Participants who are currently engaged in high-risk occupations (e.g., transportation workers, crane operators, heavy machinery operators, individuals working with sharp objects, or those requiring a high level of cognitive functioning) 15. Participants with implanted metal or electronic devices in the head or neck area, including deep brain stimulators or pacemakers, as specified in the product precautions and contraindications (dental implants are exempt) 16. Participants with cognitive impairment due to neurodevelopmental disorders (e.g., intellectual disability, developmental disorders, autism spectrum disorder) or neurodegenerative disorders (e.g., Alzheimer's disease, vascular dementia) that would make it difficult to undergo treatment with the investigational medical device 17. Participants who are pregnant or breastfeeding 18. Female participants of childbearing potential who do not agree to abstain from sexual intercourse or to use medically accepted contraception\* during the study period. \*Medically accepted methods of contraception include: condoms, consistent oral contraceptive use (≥3 months use), injectables or implantable contraceptives, or intrauterine devices (IUDs). 19. Participants who are currently participating in another clinical trial or who have participated in another clinical trial within 30 days prior to screening 20. Participants who, in the opinion of the investigator, are deemed inappropriate for participation due to ethical concerns or potential impacts on study outcomes

Primary outcome measure(s)

  • Incidence of Treatment-Emergent Adverse Events (TEAEs) — [Time Frame: Baseline to Week 4]
    The primary outcome is the incidence and severity of treatment-emergent adverse events (TEAEs) occurring from the first device application through the end of the 4-week treatment period. TEAEs include, but are not limited to, mild adverse events such as dizziness, somnolence, skin irritation, and headache. Safety will be assessed by monitoring vital signs, conducting physical examinations, and recording adverse events throughout the study period.

Trial sites (1)

FacilityCityRegionStatus
Kyungpook National University Hospital Daegu Daegu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07079215 on ClinicalTrials.gov ↗ ← All trials in South Korea